Navigation Links
Ortho Clinical Diagnostics Launches VITROS® 4600 Chemistry System for Mid- to High-Volume Laboratories
Date:7/22/2011

RARITAN, N.J., July 22, 2011 /PRNewswire/ -- Ortho Clinical Diagnostics (OCD) today announced the launch of the VITROS® 4600 Chemistry System, a state-of-the-art analyzer that delivers high-quality, reliable test results for mid- to high-volume laboratories using the same core technologies that drive reliability and efficiency throughout OCD's portfolio of products. The new analyzer completes the VITROS® x600 Family of Systems, which includes the VITROS® 5600 Integrated System and the VITROS® 3600 Immunodiagnostic System.  This portfolio of integrated instruments and broad, world-class menu of assays enable laboratories to deliver diagnostic results that help raise the standard of patient care in their institutions and networks.  

“In developing the VITROS® 4600 System, we stayed true to the value that our customers expect from OCD’s family of analyzers,” stated Holly Hillberg, Vice President, Research & Development. “The VITROS® Family of Systems provides sophisticated information management and interpretation tools that help reduce the potential for human error, improve operational efficiencies and ultimately help optimize patient care decisions.”

The VITROS® 4600 System is built on the same core VITROS® technologies that provide configurable, expandable automation solutions to streamline and standardize laboratory workflow while enhancing throughput. The proprietary technologies that drive this reliability and efficiency include:

  • MicroSlide Technology - allows for system operation independent of water supply and drainage and delivers high-quality results with 95 percent reportable result efficiency, minimizing operator interventions and maximizing ease of use.
  • MicroTip Technology - provides special chemistry menu offerings and user-defined assays in a format that is cost-effective and easy to implement with a low risk of
    '/>"/>

SOURCE Ortho-Clinical Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
2. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
3. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
4. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
5. ORTHO EVRA(R) Prescribing Information Updated
6. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
7. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
8. First Human Implant of New Archus Orthopedics Facet Replacement System
9. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
10. Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
(Date:7/14/2014)... July 14, 2014 The North America ... in North America with analysis and forecast of revenue. ... grow from around $273.1 million in 2013 to $490.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:7/14/2014)... Employers looking to lower their ... more benefit options must understand how purchasing benefits ... are the future of employee benefits. , Horizon ... BCBSNJ) is offering a free webinar, The Future ... Options, to demonstrate how HorizonSelect, its private online ...
(Date:7/14/2014)... Continuing a steady trend of growth in the ... of first-quarter success with Orange Regional Medical Center, Nexus ... by CEO and President Dr. Virginia Feldman – has ... members. Robert Poltenovage has joined the Nexus ... LPN and Angelica D’Amico have joined the Nexus Health ...
(Date:7/14/2014)... The European Lecithin Market report explains ... and projection of revenue. The Lecithin Market in Europe ... 2012 to $315.9 million by 2019, at a CAGR ... the TOC of the European Lecithin Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/14/2014)... use of antibiotics is still prevalent among terminal patients ... despite little evidence that the medications improve symptoms or ... effects. , The use of antibiotics is so engrained ... discharged from hospitals directly to a hospice program leave ... one fourth of them don,t have a documented infection ...
Breaking Medicine News(10 mins):Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 3Health News:Antibiotic use prevalent in hospice patients despite limited evidence of its value 2
... , TAMPA, Fla. , Jan. ... the United States Preventative Task Force (USPTF), the Obesity Action ... add health insurance coverage of the recommended childhood obesity treatments. ... treating childhood obesity in moderate to intensive programs helps children ...
... , MORRISTOWN, N.J. , Jan. 19 ... a leading specialty pharmaceutical company, today confirmed that its subsidiary, ... (ANDA) with the U.S. Food and Drug Administration (FDA) seeking ... the expiration of U.S. Patent No. 5,827,529.  Watson,s lidocaine topical ...
... , Berk Prepares to Return as CEO , ... President Joel Seligman today announced that on March 1 ... full-time CEO of the Medical Center while Mark B. Taubman ... of Rochester School of Medicine and Dentistry .   , "I am excited ...
... will be held in Barcelona, Spain (Centre Convencions Internacional ... 24 - Saturday 27 March 2010. The ... the only one that involves all the major players ... between clinicians, scientists and patients in a partnership of ...
... survivors wait up to five years before disclosing they were ... Montral, the Universit du Qubec Montral and the Universit ... . "The number of victims who never reveal their ... very high," says co-author Mireille Cyr, a psychology professor of ...
... closely supported by a nurse-physician primary care team are twice ... those who receive usual care, according to a study by ... The research, published online in the latest edition of the ... 18 months of a randomized controlled trial, Guided Care recipients ...
Cached Medicine News:Health News:Obesity Action Coalition Calls on Insurers and Employers to Increase Access to Childhood Obesity Treatments Based on Recent United States Preventative Task Force Recommendations 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 3Health News:New Dean of School of Medicine and Dentistry Announced 2Health News:New Dean of School of Medicine and Dentistry Announced 3Health News:Disclosing sexual abuse is critical 2Health News:Guided Care participants rate quality of health care high 2
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: